Isocyclophosphamide
Anaplastic Large Cell Lymphoma
Explore 50 assets in Anaplastic Large Cell Lymphoma →Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01979536CT.gov Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma | — | Completed | — | — | — |
NCT01590732CT.gov Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
NCT00801918CT.gov Denileukine Diftitox for Relapsed ALCL | — | Withdrawn | — | — | — |
NCT00601718CT.gov Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00354107CT.gov Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma | — | Terminated | — | — | — |
NCT00199082CT.gov Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anaplastic Large Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Isocyclophosphamide (this asset) | National Cancer Institute (NCI) | Approved | BB · 71 |
| (+)-Vincristine | Seagen Inc. | P4 | BBB |
| Crizotinib | Pfizer | P4 | BBB |
| Adriamycin | City of Hope Medical Center | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| Brentuximab Vedotin | Seagen Inc. | P3 | BBB |
| Etoposide | City of Hope Medical Center | P4 | BB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BB |
| Nivestim | Fred Hutchinson Cancer Center | P4 | BB |
+42 more in the Anaplastic Large Cell Lymphoma cohort
Other indications for Isocyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Angioimmunoblastic T-Cell Lymphoma | — | P4 | BBB · 76 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P4 | BBB · 76 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Isocyclophosphamide in Anaplastic Large Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/isocyclophosphamide-anaplastic-large-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →